Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | EBP | Q15125 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL467088 | 0.99 | SIGMAR1 (1.00) | SIGMAR1EBPTMEM97 | |
| Hydrochloric Acid SCHEMBL30527972 | 0.99 | SIGMAR1 (1.00) | SIGMAR1EBPTMEM97 | |
| Oxalic Acid SCHEMBL8728738 | 0.94 | SIGMAR1 (0.89) | SIGMAR1EBPTMEM97 | |
| SCHEMBL9073187 | 0.94 | SIGMAR1 (0.88) | SIGMAR1EBPTMEM97 | |
| SCHEMBL8196417 | 0.93 | SIGMAR1 (0.86) | SIGMAR1EBPTMEM97 | |
| Hydrochloric Acid SCHEMBL9077060 | 0.92 | SIGMAR1 (0.87) | SIGMAR1EBPTMEM97 | |
| SCHEMBL9076822 | 0.92 | SIGMAR1 (0.85) | SIGMAR1EBPTMEM97 | |
| Hydrochloric Acid SCHEMBL8189474 | 0.91 | SIGMAR1 (0.86) | SIGMAR1EBPTMEM97 | |
| Hydrochloric Acid SCHEMBL9077835 | 0.91 | SIGMAR1 (0.85) | SIGMAR1EBPTMEM97 | |
| Hydrochloric Acid SCHEMBL9077762 | 0.91 | SIGMAR1 (0.85) | SIGMAR1EBPTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012182-A | Method for synthesizing branched fatty acid ester of hydroxy fatty acid by taking natural oil containing hydroxy fatty acid as raw material | 江南大学 | 2026-05-12 | — | — | CN | claimed |
| WO-2025233557-A1 | SIGMA-1 RECEPTOR INHIBITING AGENTS FOR TREATING RHEUMATOID ARTHRITIS | UNIVERSIDAD DE GRANADA (ES) | 2025-11-13 | — | — | WO | claimed |
| CN-119818506-A | Pharmaceutical composition for preventing and/or treating pain and application thereof | 江苏海洋大学 | 2025-04-15 | — | — | CN | claimed |
| CN-118562903-B | Method for preparing diglyceride oil by solvent-free enzyme method | 江南大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119776454-A | Method for reducing free fatty acid by high acid value processing grease biological enzyme method | 无锡蔚蓝生物科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-118562903-A | Method for preparing diglyceride oil by solvent-free enzyme method | 江南大学 | 2024-08-30 | — | — | CN | claimed |
| CN-118360349-A | Preparation method and application of medium-chain fatty acid triglyceride | 广东聚石科技研究院有限公司 | 2024-07-19 | — | — | CN | claimed |
| WO-2024105225-A1 | SYNERGISTIC COMBINATIONS OF A SIGMA RECEPTOR 1 (S1R) ANTAGONIST AND A SOLUBLE EPOXIDE HYDROLASE INHIBITOR (SEHI) AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | claimed |
| CN-113853458-B | Woven cloth, method of preparing the same, and article or garment comprising the same | 尚科纺织企业工业及贸易公司 | 2024-04-30 | — | — | CN | claimed |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | UNM RAINFOREST INNOVATIONS (US) | 2023-08-24 | — | — | US | claimed |
| CN-115216497-A | Preparation method of diglyceride edible oil | 程秀梅 | 2022-10-21 | — | — | CN | claimed |
| WO-2010015040-A1 | THERAPY AND PREVENTION OF TDP-43 PROTEINOPATHY | POWMRI LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | claimed |
| EP-0717990-B1 | COMPOSITION FOR REMEDYING DRUG DEPENDENCE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2000-05-24 | — | — | EP | claimed |
| EP-0641766-B1 | ALKOXYPHENYLALKYLAMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 1998-11-11 | — | — | EP | claimed |
| EP-4748441-A2 | COMPOSITIONS COMPRISING ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2002030422-A1 | USE OF DEFINED SUBSTANCES THAT BIND TO THE SIGMA RECEPTOR FOR COMBATING SARCOMA AND CARCINOMA | MERCK PATENT GMBH (DE) | 2002-04-18 | — | — | WO | disclosed |
| EP-0717990-B1 | COMPOSITION FOR REMEDYING DRUG DEPENDENCE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | SIGMAR1 13/4885EBP 1526/4885TMEM97 50/4885 |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | SARS1, SQSTM1, ATG4A | SIGMAR1 2480/4885EBP 524/4885TMEM97 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.